top of page


Dr Alsaleh is a scientist, a published author, and an international speaker in the field of Metabolic Profiling (Metabolomics). She specialises in chronic disease prevention (e.g. cancer, diabetes, obesity, etc..). Her passion for yoga started when she got diagnosed with ADHD & anxiety disorder. Unlike pharmaceutical interventions, which caused her heart palpitation, insomnia, and loss of appetite, she found great relief after practicing yoga. The asana taught her mental focus and gave her physical strength. The meditation offered her a non-judgmental space to witness her thoughts and allowed her to feel more present. The pranayama shifted her nervous system from fight or flight mode to a calmer state of being.

Dr Munirah combines her unique academic background + her love for yoga philosophy to advise individuals, events, forums and more. She offers holistic wellness consultations, yoga classes and curate unique wellness experiences.

IMG_2896 (1).jpg
Munirah Alsaleh, PhD: Our Team


2018 PhD, Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London.

2013 MRs Clinical Research (Distinction), Imperial College London.

2010 BSc Clinical Nutrition, King Saud University.

Munirah Alsaleh, PhD: Text


  • Alsaleh, M., Leftley, Z., O’Connor, T. et al., 2021 “Mapping of population disparities in the cholangiocarcinoma urinary metabolome.” Sci Rep 11, 21286 

  • Alsaleh M, Barbera TA, Andrews RH, et al., 2019, “Mass Spectrometry: A Guide for the Clinician”, Journal of Clinical and Experimental Hepatology, 9(5), 597-606.

  • Alsaleh M, Barbera TA, Reeves HL, et al., 2019, “Characterisation of Urinary Metabolic Profiles of Cholangiocarcinoma in a United Kingdom Population”, Hepatic Medicine: Evidence and Research, 3;11:47-67

  • Alsaleh, M., Sithithaworn, P., Pkhuntikeo, N., et al., 2019, “Characterisation of the Urinary Metabolic Profile of Liver Fluke-Associated Cholangiocarcinoma.” Journal of Clinical and Experimental Hepatology, 9(6):657-675.

  • Alsaleh, M., Leftley, Z., Barbera, T., et al., 2018, “Cholangiocarcinoma: A Guide for the Non-Specialist.” International journal of general medicine, 12, 13-23.

  • Ahmad, M.S., Ashrafian, H., Alsaleh, M., and Holmes, E., 2017, “Role of Metabolic Phenotyping in Understanding Obesity and Related Conditions in Gulf Co-operation Council Countries.” Clinical Obesity, 5(6), 302-311.

  • Ahmad, M.S., Alsaleh, M., Kimhofer, T., et al., 2017. “The Metabolic Phenotype of Obesity in a Saudi Population”. Journal of Proteome Research, 16(2), 635-644.

Munirah Alsaleh, PhD: Text

International Presentations

  • 2021 – “Science Behind Ayurveda” at the Indian Embassy, Riyadh, Saudi Arabia, 2 Nov.

  • 2015 – “Urinary Metabolic Profiling in Cholangiocarcinoma” at Mining Microbes for Mankind Postgraduate symposium, Cork University, Ireland, 30, October.

  • 2015 – “Urinary Metabolic Profiling in Cholangiocarcinoma”, Merck Serono, Darmstadt, Germany, 29 – 30, June.

  • 2015 – “Bile Duct Cancer Biomarkers in Thailand” in the Non-Communicable Disease Forum – Cancer in Low Income Countries, St Mary’s Hospital, Imperial College London, London, United Kingdom, 18 June.

  • 2014 – “Human Urine Metabolome in Cancer Screening and Diagnosis”, oral presentation at Burden of Cancer in Gulf Region Conference, Riyadh, Saudi Arabia, 21-23 Oct.

  • 2014 – “Prognostic and Diagnostic Metabonomics Profiling Approach in Cholangiocarcinoma” at Gut Microbiome Research Using Molecular Biology and Multi-Omics Technologies Symposium, Imperial College London, United Kingdom, 14 Sep.

  • 2014 – “Diagnostic and Prognostic Metabolic Profiling of Diet, Social and Environmental Influences on The Development of Liver Cancer” presentation for Technologie Servier, Orléans, France, 6 June.

  • 2014 – “Cholangiocarcinomal Prognostic and Diagnostic Biomarkers” at Cholangiocarcinoma: Shared Disease Burden in the UK and Southeast Asia, in Khon Kaen University, Thailand, 12 – 14 March.

Munirah Alsaleh, PhD: Text
bottom of page